|Day's Range||150.62 - 150.86|
|52 Week Range||129.20 - 158.11|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.44%|
Bristol-Myers Squibb’s top line rose 12% to ~$4.9 billion in 1Q17, driven by an operational growth of 13% in revenues.
Speaking at MedCity INVEST, a national healthcare investing conference in Chicago hosted by MedCity News, Jonathan Norris of Silicon Valley Bank, alongside Ryan Jalowiecki from PwC, highlighted the latest trends in the public healthcare markets. If you are a serious biopharma investor, you won't want to miss this.
Apart from Pfizer’s (PFE) product developments, let's take a look at a few of the recent pipeline and corporate developments.